Global Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes: Results from DISCOVER
In this medfyle
Expert commentary by Michelle Welch, MD FACE
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2021 - 81st Scientific Sessions and presented by:
Suzanne V. Arnold, MD, MHA
Saint Luke’s Mid America Heart Institute
Kansas City, MO, USA
The content is produced by Infomedica, the official reporting partner of ADA 2021.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Michelle Welch, MD, FACE
Diabetes and Metabolism Specialists
Consano Clinical Research
About the Expert
Michelle Welch, MD, FACE
Diabetes and Metabolism Specialists
Consano Clinical Research
President, Diabetes and Metabolism Specialists, San Antonio, TX
Dr. Michelle D. Welch is board-certified in Internal Medicine, and Endocrinology, Diabetes, and Metabolism. She is the founder and current president of Diabetes and Metabolism Specialists in San Antonio.
A native of California, Michelle earned her Bachelor of Science degree from Pepperdine University and was a candidate for a Master of Science degree at the University of Southern California before being accepted to Albany Medical College in Albany, New York. After earning her Doctor of Medicine degree from Albany Medical College in 1997, Michelle moved to what has been her home ever since, to complete her Internship and Residency in Internal Medicine at the University of Texas Health Science Center at San Antonio (UTHSCSA). It was there that Michelle developed a deep interest in the field of endocrinology due in large part to its prevalence in the community. This interest led Michelle to complete a fellowship in Endocrinology, Diabetes, and Metabolism at UTHSCSA in 2002.
Upon completion of her Fellowship, Michelle joined a local practice group where she quickly earned the recognition of her peers for her clinical knowledge and patient-care compassion. A desire to utilize the latest in diagnostic modalities and therapeutic treatments in the rapidly developing field of endocrinology led Michelle to open her practice, Diabetes and Metabolism Specialists, in 2005. The practice physicians, nurse practitioners, and dieticians offer comprehensive endocrine care to thousands of patients each year from San Antonio and the surrounding areas.
In addition to her clinical practice, Dr. Welch is the principal investigator of multiple pharmacological research studies at Consano Clinical Research, LLC located at her practice location. She holds multiple Advisory Board positions and is a sought-after speaker for major pharmaceutical companies.
In her personal life, she enjoys spending time with her family and riding her horse, Kinsman.
Disclosures:
Research: Regeneron, Janssen, Novo Nordisk, AstraZeneca, Kowa, Novartis, Lilly, Abbvie, Pfizer, Senseonics, GSK, Sanofi, Medtronic, Dexcom, Abbott
Speaker: AstraZeneca, BI, Lilly, Mankind, Amgen,Senseonics, Janssen
References
1. Arnold SV, Inzucchi SE, Tang F, et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project. Eur J PrevCardiol 2017;24(15):1637–45.
2. Arnold SV, de Lemos JA, Rosenson RS, et al. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation 2019;140(7):618–20.
